The fetal safety of hydrocortisone-pramoxine (Proctofoam-HC) for the treatment of hemorrhoids in late pregnancy

J Obstet Gynaecol Can. 2011 Feb;33(2):153-158. doi: 10.1016/S1701-2163(16)34802-2.

Abstract

Objective: Fetal safety has never been studied for any drug used in the treatment of hemorrhoids. Proctofoam-HC is a combination of a corticosteroid and a local anaesthetic that is proven effective for the treatment of hemorrhoids. The objective of this study was to assess prospectively the fetal safety of third trimester exposure to Proctofoam-HC.

Methods: In a multicentre study, 204 [corrected] women exposed to Proctofoam-HC in the third trimester and a similar number of control pregnant women were followed up postnatally.

Results: When compared to controls exposure to Proctofoam-HC was not associated with any adverse fetal effects on birth weight, gestational age, rates of prematurity, or pre- or postnatal complications.

Conclusion: Proctofoam-HC is safe to use in the treatment of hemorrhoids in late pregnancy.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anesthetics, Local / adverse effects*
  • Anti-Inflammatory Agents / adverse effects*
  • Birth Weight
  • Drug Combinations
  • Female
  • Fetal Development / drug effects*
  • Hemorrhoids / drug therapy*
  • Humans
  • Hydrocortisone / adverse effects*
  • Morpholines / adverse effects*
  • Pregnancy
  • Pregnancy Complications / drug therapy*
  • Pregnancy Trimester, Third

Substances

  • Anesthetics, Local
  • Anti-Inflammatory Agents
  • Drug Combinations
  • Morpholines
  • proctofoam-HC
  • Hydrocortisone